A twice-yearly injectable drug, lenacapavir, hailed as a breakthrough in HIV prevention, could be available in Canada by ...

New player emerges in 23andMe bankruptcy An Indian drug company has big plans for the East Bay An Indian drug company has big ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an antiviral drug for HIV prevention based on his findings.

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the ...

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue ...

Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from ...

The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...

The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences ...